What metabolic and inflammatory pathways change with disease progression or treatment?
What exposure signals modify genetic risk?
Which metabolic signals precede clinical disease?
Which patients are most likely to respond to a given therapy?
Identify molecular signatures associated with disease onset, progression, and complication risk by measuring dynamic proteins, metabolites, and lipids linked to metabolic dysfunction and inflammation.
Discover biomarkers that read out treatment response, target engagement, and mechanism of action, enabling early detection of subtle metabolic changes and more informed go/no‑go decisions.
Advance promising biomarkers from discovery into translational and early clinical studies by confirming human relevance and reproducibility across cohorts and timepoints.
We’ve innovated our methods with a focus on profiling dynamic biology at a new depth and scale, capturing proteins, metabolites, and lipids that change with metabolic diseases and treatment. These offerings include:
See the exciting findings from a multi-omics study utilizing the NULISA Inflammation Panel 250 alongside Sapient’s mass spectrometry-based discovery proteomics and metabolomics to characterize changes in inflammatory markers observed following GLP-1 therapy.
DynamiQ is Sapient’s large-scale, longitudinal molecular‑clinical database, built from tens of thousands of deeply phenotyped human samples collected across multiple timepoints. For cardiometabolic biomarker discovery, DynamiQ enables:
Confirm & contextualize molecular signals over time and across patient journeys.
Layer your data and ours to orthogonally validate findings and extend discoveries.
Ground biomarker discovery in real patient data to bridge the translational gap.
